RxSight, Inc.
RXST · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $30,340 | $33,637 | $37,895 | $40,214 |
| % Growth | -9.8% | -11.2% | -5.8% | – |
| Cost of Goods Sold | $6,113 | $8,447 | $9,566 | $11,426 |
| Gross Profit | $24,227 | $25,190 | $28,329 | $28,788 |
| % Margin | 79.9% | 74.9% | 74.8% | 71.6% |
| R&D Expenses | $9,060 | $10,217 | $10,367 | $9,207 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $27,345 | $28,976 | $28,636 | $28,209 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $36,405 | $39,193 | $39,003 | $37,416 |
| Operating Income | -$12,178 | -$14,003 | -$10,674 | -$8,628 |
| % Margin | -40.1% | -41.6% | -28.2% | -21.5% |
| Other Income/Exp. Net | $2,372 | $2,249 | $2,502 | $2,702 |
| Pre-Tax Income | -$9,806 | -$11,754 | -$8,172 | -$5,926 |
| Tax Expense | $10 | $32 | $18 | $12 |
| Net Income | -$9,816 | -$11,786 | -$8,190 | -$5,938 |
| % Margin | -32.4% | -35% | -21.6% | -14.8% |
| EPS | -0.24 | -0.29 | -0.2 | -0.15 |
| % Growth | 17.2% | -45% | -33.3% | – |
| EPS Diluted | -0.24 | -0.29 | -0.2 | -0.15 |
| Weighted Avg Shares Out | 40,965 | 40,744 | 40,510 | 40,357 |
| Weighted Avg Shares Out Dil | 40,965 | 40,744 | 40,510 | 40,357 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $2,254 | $2,508 | $2,707 |
| Interest Expense | $4 | $5 | $6 | $5 |
| Depreciation & Amortization | $854 | $785 | $785 | $523 |
| EBITDA | -$8,948 | -$10,964 | -$7,381 | -$5,398 |
| % Margin | -29.5% | -32.6% | -19.5% | -13.4% |